VolitionRx announces pricing of underwritten public offering of 3 million shares at a public offering price of $2.00 eachProactive Investors • 07/29/22
VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common StockPRNewsWire • 07/29/22
New NETs Data Presented at International Society on Thrombosis and Haemostasis (ISTH) CongressPRNewsWire • 07/13/22
VolitionRx says Nu.Q NETs test gets CE mark enabling clinical use in over 27 countries across EuropeProactive Investors • 05/31/22
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
VolitionRx reports strong 1Q anchored by $10M milestone payment from Heska for Nu.Q Vet Cancer Screening TestProactive Investors • 05/11/22
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business UpdatePRNewsWire • 05/11/22
VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business UpdatePRNewsWire • 05/06/22
VolitionRx launches its Nu.Q Vet Cancer Test in Asia through distributor SAGE HealthcareProactive Investors • 04/25/22
Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE HealthcarePRNewsWire • 04/25/22
VolitionRx appoints industry veteran Sharon Ballesteros as its US head of quality and development processProactive Investors • 04/06/22
Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development ProcessPRNewsWire • 04/06/22
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
VolitionRx makes ‘good progress' in key areas as it ends 2021 with over $20M in cashProactive Investors • 03/31/22
VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business UpdatePRNewsWire • 03/30/22
VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening testProactive Investors • 03/29/22
Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of CarePRNewsWire • 03/29/22
Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer ScreenPRNewsWire • 03/29/22
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business UpdatePRNewsWire • 03/28/22
Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomasPRNewsWire • 01/20/22
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in AsiaPRNewsWire • 12/16/21